# US 2018/0022730 A1 · Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022730 A1
- Document ID: US20180022730A1
- Status: Published application
- Kind: A1
- Application number: 15/521,107
- Filed: 2015-10-21
- Published: 2018-01-25
- Earliest claimed: 2014-10-22
- Assignees: Board of Regents, The University of Texas System; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Applicants: The Board of Regents of the University of Texas System; Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- Inventors: Rolf A. BREKKEN; Ke DING; Xiaomei REN; Zhengchao TU; Zhen WANG; Kristina Y. AGUILERA
- Web page: https://patentgrep.com/patent/US20180022730A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.

## Claims

### Claim 1

A compound of the formula:
wherein:
A is —NR8C(O)— or —C(O)NR8—; wherein:
R8 is hydrogen, alkyl(C≦6), or substituted alkyl(C≦6);
R1 is aryl(C≦12), heteroaryl(C≦12), or a substituted version of either of these groups;
R2, R3, and R3′ are each independently hydrogen, alkyl(C≦12), cycloalkyl(C≦12), substituted alkyl(C≦12), or substituted cycloalkyl(C≦12);
R4 is hydrogen, alkyl(C≦12), cycloalkyl(C≦12), aryl(C≦12), substituted alkyl(C≦12), substituted cycloalkyl(C≦12), or substituted aryl(C≦12),
R5 is hydrogen, heteroaryl(C≦12), —X—R9, wherein:
X is a covalent bond, alkanediyl(C≦8), or substituted alkanediyl(C≦8);
R9 is amino or heterocycloalkyl(C≦12), heteroaryl(C≦12), alkylamino(C≦12), dialkylamino(C≦12), or a substituted version of any of these groups; or a group of the formula:
wherein:
R10 is hydrogen, alkyl(C≦12), cycloalkyl(C≦12), substituted alkyl(C≦12), or substituted cycloalkyl(C≦12); and
p and q are each 0, 1, or 2;
R6 and R7 are each independently amino, cyano, halo, hydroxy, hydroxysulfonyl, nitro, sulfonamide; or
alkyl(C≦8), acyl(C≦8), alkoxy(C≦8), amido(C≦8), acyloxy(C≦8), alkylamino(C≦8), or dialkylamino(C≦8); and
m and n are each independently 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is further defined as:
wherein: A, R1, R3, R3′, R4, R5, R6, and n are as defined above;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1, 2)

The compound of either claim 1 or claim 2, wherein the compound is further defined as:
wherein: A, R1, R3, R3′, R4, R5, R6, and n are as defined above;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of claims 1-3, wherein R1 is heteroaryl(C≦12).

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is 5-pyrimidinyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1-5, wherein R3 is alkyl(C≦12).

### Claim 7 (depends on 6)

The compound of claim 6, wherein R3 is methyl or ethyl.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1-5, wherein R3 is hydrogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound according to any one of claims 1-8, wherein R3′ is hydrogen.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9, wherein R4 is alkyl(C≦12) or substituted alkyl(C≦12).

### Claim 11 (depends on 10)

The compound of claim 10, wherein R4 is alkyl(C≦12).

### Claim 12 (depends on 11)

The compound of claim 11, wherein R4 is methyl, ethyl, or isopropyl.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R4 is substituted alkyl(C≦12).

### Claim 14 (depends on 13)

The compound of claim 13, wherein R4 is trifluoromethyl.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9, wherein R4 is cycloalkyl(C≦12) or substituted cycloalkyl(C≦12).

### Claim 16 (depends on 15)

The compound of claim 15, wherein R4 is cycloalkyl(C≦12).

### Claim 17 (depends on 16)

The compound of claim 16, wherein R4 is cyclopropyl, cyclopentyl, or cyclohexyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1-9, wherein R4 is aryl(C≦12).

### Claim 19 (depends on 18)

The compound of claim 18, wherein R4 is phenyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound according to any one of claims 1-19, wherein R5 is hydrogen.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound according to any one of claims 1-19, wherein R5 is heteroaryl(C≦12).

### Claim 22 (depends on 21)

The compound of claim 21, wherein R5 is 4-methylimidazolyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound according to any one of claims 1-19, wherein R5 is —X—R9, wherein:
X is a covalent bond, alkanediyl(C≦8), or substituted alkanediyl(C≦8);
R9 is amino or heterocycloalkyl(C≦12), heteroaryl(C≦12), alkylamino(C≦12), dialkylamino(C≦12), or a substituted version of any of these groups; or a group of the formula:
wherein:
R10 is hydrogen, alkyl(C≦12), cycloalkyl(C≦12), substituted alkyl(C≦12), or substituted cycloalkyl(C≦12); and
p and q are each 0, 1, or 2.

### Claim 24 (depends on 23)

The compound of claim 23, wherein X is alkanediyl(C≦8).

### Claim 25 (depends on 24)

The compound of claim 24, wherein X is —CH2— or —CH2CH2—.

### Claim 26 (depends on 23, 24, 25)

The compound according to any one of claims 23-25, wherein R9 is heterocycloalkyl(C≦12) or a substituted heterocycloalkyl(C≦12).

### Claim 27 (depends on 26)

The compound of claim 26, wherein R9 is N-1,4-thiazinanyl, N-morpholinyl, N-piperidinyl, N-pyrrolidinyl, or N-3-dimethylaminopyrrolidinyl.

### Claim 28 (depends on 23, 24, 25)

The compound according to any one of claims 23-25, wherein R9 is dialkylamino(C≦12) or substituted dialkylamino(C≦12).

### Claim 29 (depends on 28)

The compound of claim 28, wherein R9 is —N(CH3)CH2CH2N(CH3)2.

### Claim 30 (depends on 23, 24, 25)

The compound according to any one of claims 23-25, wherein R9 is:
wherein:
R10 is hydrogen, alkyl(C≦12), cycloalkyl(C≦12), substituted alkyl(C≦12), or substituted cycloalkyl(C≦12); and
p and q are each 0, 1, or 2.

### Claim 31 (depends on 30)

The compound of claim 30, wherein R10 is alkyl(C≦12) or substituted alkyl(C≦12).

### Claim 32 (depends on 31)

The compound of claim 31, wherein R10 is methyl or ethyl.

### Claim 33 (depends on 30)

The compound of claim 30, wherein R10 is cycloalkyl(C≦12) or substituted cycloalkyl(C≦12).

### Claim 34 (depends on 33)

The compound of claim 33, wherein R10 is cyclohexyl.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The compound according to any one of claims 30-34, wherein p is 1.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The compound according to any one of claims 30-35, wherein q is 1.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35)

The compound according to any one of claims 30-35, wherein q is 2.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound according to any one of claims 1-37, wherein m is 0.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound according to any one of claims 1-37, wherein m is 1.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound according to any one of claims 1-39, wherein R7 is alkyl(C≦8) or substituted alkyl(C≦8).

### Claim 41 (depends on 40)

The compound of claim 40, wherein R7 is methyl.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound according to any one of claims 1-39, wherein R7 is halo.

### Claim 43 (depends on 42)

The compound of claim 42, wherein R7 is fluoro or chloro.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound according to any one of claims 1-43, wherein the compound is further defined as:
or a pharmaceutically acceptable salt thereof.

### Claim 45

A compound of the formula:
4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(quinolin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4,4-dimethyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-chloro-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(4-methyl-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(2-(4-methylpiperazin-1-yl)ethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-((4-methyl-1,4-diazepan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-ethyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-isopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-ethylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(morpholinomethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(piperidin-1-ylmethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((dimethylamino)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclohexyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-(((R)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-fluoro-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-tert-butyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(5-((4-methylpiperazin-1-yl)methyl)biphenyl-3-yl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
3-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclopentyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-cyclohexylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-ethyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(thiomorpholinomethyl)-5-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
3-((4-methylpiperazin-1-yl)methyl)-N-(2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-(trifluoromethyl)benzamide;
(S)-4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
(R)-4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
(S)—N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide;
(R)—N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide;
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A pharmaceutical composition comprising:
(a) a compound according to any one of claims 1-45; and
(b) a pharmaceutically acceptable carrier.

### Claim 47 (depends on 46)

The pharmaceutical composition of claim 46, wherein the pharmaceutical composition further comprises a second chemotherapeutic compound.

### Claim 48 (depends on 47)

The pharmaceutical composition of claim 47, wherein the second chemotherapeutic compound is a nucleoside analog chemotherapeutic compound.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the nucleoside analog chemotherapeutic compound is gemcitabine.

### Claim 50 (depends on 47)

The pharmaceutical composition of claim 47, wherein the second chemotherapeutic compound is a taxane.

### Claim 51 (depends on 50)

The pharmaceutical composition of claim 50, wherein the second chemotherapeutic compound is paclitaxel.

### Claim 52 (depends on 46, 47, 48, 49, 50, 51)

The pharmaceutical composition according to any one of claims 46-51, wherein the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition is formulated for oral administration.

### Claim 54 (depends on 46, 47, 48, 49, 50, 51, 52, 53)

The pharmaceutical composition according to any one of claims 46-53, wherein the pharmaceutical composition is formulated as a unit dose.

### Claim 55

A pharmaceutical composition comprising:
(a) a compound of the formula:
and
(b) a second chemotherapeutic compound.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 57 (depends on 55, 56)

The pharmaceutical composition of either claim 55 or claim 56, wherein the pharmaceutical composition is formulated for oral administration.

### Claim 58 (depends on 55, 56, 57)

The pharmaceutical composition according to any one of claims 55-57, wherein the second chemotherapeutic compound is a nucleoside analog.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58, wherein the second chemotherapeutic compound is gemcitabine.

### Claim 60 (depends on 55, 56, 57)

The pharmaceutical composition according to any one of claims 55-57, wherein the second chemotherapeutic compound is a taxane.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the second chemotherapeutic compound is paclitaxel.

### Claim 62 (depends on 55, 56, 57)

The pharmaceutical composition according to any one of claims 55-57, wherein the composition is formulated as a unit dose.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound or composition according to any one of claims 1-62.

### Claim 64 (depends on 63)

The method of claim 63, wherein the disease or disorder is related to inflammation.

### Claim 65 (depends on 64)

The method of claim 64, wherein the disease or disorder is kidney fibrosis, liver fibrosis, lung fibrosis, skin scars, or atherosclerosis.

### Claim 66 (depends on 63)

The method of claim 63, wherein the disease or disorder is cancer.

### Claim 67 (depends on 66)

The method of claim 66, wherein the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.

### Claim 68 (depends on 66)

The method of claim 66, wherein the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, gastrointestinal tract, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.

### Claim 69 (depends on 66, 67, 68)

The method according to any one of claims 66-68, wherein the cancer is a cancer of the lung, breast, brain, ovary, head and neck, liver, pancreas, or prostate.

### Claim 70 (depends on 69)

The method of claim 69, wherein the cancer is a cancer of the pancreas.

### Claim 71 (depends on 70)

The method of claim 70, wherein the cancer is pancreatic ductal adenocarcinoma.

### Claim 72 (depends on 63, 64, 65, 66, 67, 68, 69)

The method according to any one of claims 63-69, wherein the compound is administered to the patient once.

### Claim 73 (depends on 63, 64, 65, 66, 67, 68, 69)

The method according to any one of claims 63-69, wherein the compound is administered to the patient two or more times.

### Claim 74 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method according to any one of claims 63-73, wherein the method further comprises a second therapy.

### Claim 75 (depends on 74)

The method of claim 74, wherein the second therapy is one or more therapeutic agents, a surgery, a radiotherapy, or an immunotherapy.

### Claim 76 (depends on 74, 75)

The method of either claim 74 or claim 75, wherein the second therapy is a chemotherapeutic agent.

### Claim 77 (depends on 76)

The method of claim 76, wherein the second therapy is a nucleoside analog chemotherapeutic agent.

### Claim 78 (depends on 77)

The method of claim 77, wherein the nucleoside analog chemotherapeutic agent is gemcitabine.

### Claim 79 (depends on 76)

The method of claim 76, wherein the second therapy is a taxane.

### Claim 80 (depends on 79)

The method of claim 79, wherein the second therapy is paclitaxel.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of inhibiting discoidin domain receptor (DDR) protein comprising contacting the protein with a compound or composition according to any one of claims 1-62 in an amount sufficient to inhibit the protein.

### Claim 82 (depends on 81)

The method of claim 81, wherein the protein is the discoidin domain receptor 1 protein (DDR1).

### Claim 83 (depends on 81, 82)

The method of either claim 81 or claim 82, wherein the method is performed in vivo.

### Claim 84 (depends on 81, 82)

The method of either claim 81 or claim 82, wherein the method is performed in vitro.

### Claim 85 (depends on 83)

The method of claim 83, wherein the method is performed in vivo and comprises administering the compound to a patient in need thereof.

### Claim 86 (depends on 85)

The method of claim 85, wherein the inhibition of DDR1 protein is sufficient to treat a disease or disorder.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of:
(a) a compound or composition according to any one of claims 1-62; and
(b) a second chemotherapeutic compound.

### Claim 88 (depends on 87)

The method of claim 87, wherein the cancer is a cancer of the lung, breast, brain, ovary, head and neck, liver, pancreas, or prostate.

### Claim 89 (depends on 88)

The method of claim 88, wherein the cancer is a cancer of the pancreas.

### Claim 90 (depends on 89)

The method of claim 89, wherein the cancer is pancreatic ductal adenocarcinoma.

### Claim 91 (depends on 87, 88, 89, 90)

The method according to any one of claims 87-90, wherein the method comprises administering the compound or composition in a ratio from about 1:2 to about 5:1 relative to the second chemotherapeutic compound.

### Claim 92 (depends on 91)

The method of claim 91, wherein the ratio of the compound or composition is 2:1 relative to the second chemotherapeutic compound.

### Claim 93 (depends on 87, 88, 89, 90, 91, 92)

The method according to any one of claims 87-92, wherein the second chemotherapeutic compound is a nucleoside analog.

### Claim 94 (depends on 93)

The method of claim 93, wherein the second chemotherapeutic compound is gemcitabine.

### Claim 95 (depends on 87, 88, 89, 90, 91, 92)

The method according to any one of claims 87-92, wherein the second chemotherapeutic compound is a taxane.

### Claim 96 (depends on 95)

The method of claim 95, wherein the second chemotherapeutic compound is paclitaxel.

### Claim 97

A compound of formula (IV) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof:
wherein L1 is independently selected as —CONH— or —NHCO—;
is independently selected from:
a) single heterocycles like
b) fused heterocycles like
R1, R2, R3 are independently selected from:
a) H;
b) C1˜C4 alkyl;
R2, R3 can further form tri, tetra, penta ring structure with the carbon atom where they are linked in the C ring;
R4, R5, R6 is independently selected from:
a) H;
b) halogen (F, Cl, Br);
c) C1˜C4 alkyl;
d) C3˜C6 cycloalkyl;
e) C1˜C4 alkyl containing F;
f) aryl, Het;
aryl can be phenyl, or substituted phenyl; Het is defined as the nonaromatic heterocycle, or aromatic heterocycle containing 5˜6 atoms, which contains 1˜4 hetero atoms such as O, N, S. Alkyl or cycloalkyl will be incorporated into any C or N position in which Het can be substituted.

### Claim 98 (depends on 97)

The compound of claim 97, wherein R1, R2, R3 is independently selected from:
a) H;
b) methyl, ethyl, propyl, isopropyl, cyclopropyl;
R2, R3 can further form tri, tetra, penta ring structure with the carbon atom where they are linked in the C ring.

### Claim 99 (depends on 97)

The compound of claim 97, wherein D ring is selected from:
R4 is independently selected from:
a) halogen (F, Cl, Br);
b) C1˜C4 alkyl;
c) C3˜C6 cycloalkyl;
d) C1˜C4 alkyl containing F;
e) aryl;
Aryl can be phenyl, or substituted phenyl;
R5 is independently selected from H, F, Cl, Br, Me, OMe;
R7 or R8 is independently selected from:
a) H;
b) C1˜C3 alkyl;
c) C1˜C3 alkyl containing F;
d) C3˜C6 cycloalkyl;
R7 and R8 can further form penta-, hexa-, hepta- or octatomic ring structure through C, O, N, S atoms. Alkyl or cycloalkyl will be incorporated into any C or N position in the ring which can be substituted; preferably,
is independently selected from:

### Claim 100 (depends on 97, 98, 99)

The compound according to any one of claims 97-99, wherein the compound of formula (IV) is specially selected from:
wherein
L1 is independently selected as —CONH— or —NHCO—;
is independently selected from:
R1, R2, R3, R4, R5, R7, R8 have the same definition as above mentioned.

### Claim 101 (depends on 100)

The compound of claim 100, wherein the compound of formula (IV) is specially selected from:
4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(quinolin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyridin-3-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4,4-dimethyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-chloro-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(4-methyl-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(2-(4-methylpiperazin-1-yl)ethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-((4-methyl-1,4-diazepan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-ethyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-isopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-ethylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(morpholinomethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(piperidin-1-ylmethyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((dimethylamino)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclohexyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquino line-7-carboxamide;
N-(3-(((2-(dimethylamino)ethyl)(methyl)amino)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-(((R)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-(((S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(4-fluoro-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-tert-butyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-N-(5-((4-methylpiperazin-1-yl)methyl)biphenyl-3-yl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
3-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-cyclopentyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
N-(3-((4-cyclohexylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-ethyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
4-methyl-2-(pyrimidin-5-yl)-N-(3-(thiomorpholinomethyl)-5-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
3-((4-methylpiperazin-1-yl)methyl)-N-(2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-5-(trifluoromethyl)benzamide;
(S)-4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
(R)-4-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide;
(S)—N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide; and
(R)—N-(4-methyl-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)benzamide.

### Claim 102 (depends on 97, 98, 99, 100, 101)

A pharmaceutical composition comprising a compound according to any one of claims 97-101 or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof and a pharmaceutically acceptable carrier, solvent, buffer or diluent.

### Claim 103 (depends on 97, 98, 99, 100, 101)

A method of treating a subject having inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar and atherosclerosis, and cancer comprising administering to said subject a compound according to any one of claims 97-101 or a pharmaceutically acceptable salt, stereoisomer or pro-drug thereof.
